215 related articles for article (PubMed ID: 26265483)
1. Treatment with high dose of erythropoiesis-stimulating agents and mortality: analysis with a sequential Cox approach and a marginal structural model.
Suttorp MM; Hoekstra T; Mittelman M; Ott I; Krediet RT; Dekker FW; Putter H
Pharmacoepidemiol Drug Saf; 2015 Oct; 24(10):1068-75. PubMed ID: 26265483
[TBL] [Abstract][Full Text] [Related]
2. Association of a change in erythropoiesis-stimulating agent dose during hospitalization and subsequent hemoglobin levels and transfusions in hemodialysis patients.
Wong BC; Ravani P; Manns BJ; Lewin A; Zhang X; Chin R; Hemmelgarn BR; Tonelli M; Oliver MJ; Quinn RR
Am J Kidney Dis; 2013 Nov; 62(5):947-52. PubMed ID: 23856380
[TBL] [Abstract][Full Text] [Related]
3. Higher doses of erythropoietin-stimulating agents and hyporesponsiveness to their effects are associated with increased mortality among prevalent hemodialysis patients.
Nishio A; Chhatkuli BP; Ma JZ; Kalantari K
Blood Purif; 2013; 36(1):29-36. PubMed ID: 23735569
[TBL] [Abstract][Full Text] [Related]
4. Erythropoiesis-stimulating agents and thrombotic events in dialysis patients.
Suttorp MM; Hoekstra T; Ocak G; van Diepen AT; Ott I; Mittelman M; Rabelink TJ; Krediet RT; Dekker FW
Thromb Res; 2014 Nov; 134(5):1081-6. PubMed ID: 25242244
[TBL] [Abstract][Full Text] [Related]
5. The impact of hyporesponsiveness to erythropoietin-stimulating agents on time-dependent mortality risk among CKD stage 5D patients: a single-center cohort study.
Ishigami J; Onishi T; Shikuma S; Akita W; Mori Y; Asai T; Kuwahara M; Sasaki S; Tsukamoto Y
Clin Exp Nephrol; 2013 Feb; 17(1):106-14. PubMed ID: 22752396
[TBL] [Abstract][Full Text] [Related]
6. Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients.
Suttorp MM; Hoekstra T; Rotmans JI; Ott I; Mittelman M; Krediet RT; Dekker FW
BMC Nephrol; 2013 Sep; 14():200. PubMed ID: 24066978
[TBL] [Abstract][Full Text] [Related]
7. Peginesatide in patients with anemia undergoing hemodialysis.
Fishbane S; Schiller B; Locatelli F; Covic AC; Provenzano R; Wiecek A; Levin NW; Kaplan M; Macdougall IC; Francisco C; Mayo MR; Polu KR; Duliege AM; Besarab A;
N Engl J Med; 2013 Jan; 368(4):307-19. PubMed ID: 23343061
[TBL] [Abstract][Full Text] [Related]
8. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis.
Macdougall IC; Provenzano R; Sharma A; Spinowitz BS; Schmidt RJ; Pergola PE; Zabaneh RI; Tong-Starksen S; Mayo MR; Tang H; Polu KR; Duliege AM; Fishbane S;
N Engl J Med; 2013 Jan; 368(4):320-32. PubMed ID: 23343062
[TBL] [Abstract][Full Text] [Related]
9. Characterization of chronic and acute ESA hyporesponse: a retrospective cohort study of hemodialysis patients.
Sibbel SP; Koro CE; Brunelli SM; Cobitz AR
BMC Nephrol; 2015 Aug; 16():144. PubMed ID: 26283069
[TBL] [Abstract][Full Text] [Related]
10. Low versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial.
Saglimbene V; Palmer SC; Craig JC; Ruospo M; Nicolucci A; Tonelli M; Johnson D; Lucisano G; Williams G; Valentini M; D'Alonzo D; Pellegrini F; Strippoli P; Salomone M; Santoro A; Maffei S; Hegbrant J; Tognoni G; Strippoli GF;
PLoS One; 2017; 12(3):e0172735. PubMed ID: 28249030
[TBL] [Abstract][Full Text] [Related]
11. Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan.
Fukuma S; Yamaguchi T; Hashimoto S; Nakai S; Iseki K; Tsubakihara Y; Fukuhara S
Am J Kidney Dis; 2012 Jan; 59(1):108-16. PubMed ID: 21890255
[TBL] [Abstract][Full Text] [Related]
12. Mortality associated with dose response of erythropoiesis-stimulating agents in hemodialysis versus peritoneal dialysis patients.
Duong U; Kalantar-Zadeh K; Molnar MZ; Zaritsky JJ; Teitelbaum I; Kovesdy CP; Mehrotra R
Am J Nephrol; 2012; 35(2):198-208. PubMed ID: 22286821
[TBL] [Abstract][Full Text] [Related]
13. Increased mortality in haemodialysis patients administered high doses of erythropoiesis-stimulating agents: a propensity score-matched analysis.
Pérez-García R; Varas J; Cives A; Martín-Malo A; Aljama P; Ramos R; Pascual J; Stuard S; Canaud B; Merello JI;
Nephrol Dial Transplant; 2018 Apr; 33(4):690-699. PubMed ID: 29036505
[TBL] [Abstract][Full Text] [Related]
14. It's time to compare anemia management strategies in hemodialysis.
Coyne DW
Clin J Am Soc Nephrol; 2010 Apr; 5(4):740-2. PubMed ID: 20299363
[TBL] [Abstract][Full Text] [Related]
15. Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients.
Kuragano T; Matsumura O; Matsuda A; Hara T; Kiyomoto H; Murata T; Kitamura K; Fujimoto S; Hase H; Joki N; Fukatsu A; Inoue T; Itakura I; Nakanishi T
Kidney Int; 2014 Oct; 86(4):845-54. PubMed ID: 24759150
[TBL] [Abstract][Full Text] [Related]
16. Mortality in incident haemodialysis patients: time-dependent haemoglobin levels and erythropoiesis-stimulating agent dose are independent predictive factors in the ANSWER study.
Fort J; Cuevas X; García F; Pérez-García R; Lladós F; Lozano J; Martín-Malo A;
Nephrol Dial Transplant; 2010 Aug; 25(8):2702-10. PubMed ID: 20176608
[TBL] [Abstract][Full Text] [Related]
17. Mortality in dialysis patients may not be associated with ESA dose: a 2-year prospective observational study.
McMahon LP; Cai MX; Baweja S; Holt SG; Kent AB; Perkovic V; Leikis MJ; Becker GJ
BMC Nephrol; 2012 Jun; 13():40. PubMed ID: 22702540
[TBL] [Abstract][Full Text] [Related]
18. Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study.
Ogawa T; Shimizu H; Kyono A; Sato M; Yamashita T; Otsuka K; Nitta K
Int Urol Nephrol; 2014 Jan; 46(1):151-9. PubMed ID: 23807369
[TBL] [Abstract][Full Text] [Related]
19. Comparative Effectiveness of Iron and Erythropoiesis-Stimulating Agent Dosing on Health-Related Quality of Life in Patients Receiving Hemodialysis.
Freburger JK; Ellis AR; Wang L; Butler AM; Kshirsagar AV; Winkelmayer WC; Brookhart MA
Am J Kidney Dis; 2016 Feb; 67(2):271-82. PubMed ID: 26508682
[TBL] [Abstract][Full Text] [Related]
20. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
Yong K; Kairaitis L
Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
